From the study of purine synthesis, urate crystal deposition in joints and puricase interaction with plasma protein, a system of first order differential equations is obtained. The existence and uniqueness of the solutions of the system of equations is established. Some controllability and stabilizability results are obtained via the Pontryagins Maximum Principles.
Model Formulation
Let x(t) denote the amount of uric acid in serum at time t; p(t), the amount of puricase in serum at the same time time t; x 0 , the equilibrium level of uric acid in a healthy state; p 0 , the equilibrium level of uricase in a healthy state; g 1 , the rate of exogeneous supply of uric acid through food intake; g 2 , the rate of exogeneous supply of uricase, through injection; a 1 , the rate at which serum uric acid crystallizes into urate; a 2 , the rate at which the concentration of urate is decreased by uricase; a 3 , the rate at which the dosage of uricase is increased when serum uric acid level rises; a 4 , the rate at which uricase depletes stores of serum urate crystals; u f , uric acid from food; u p , uricase from puricase.
We have the following representation
Following the information in the diagram above, the state (governing) equations have the form ⎧ ⎪ ⎪ ⎨ ⎪ ⎪ ⎩ dx dt = −a 1 x − a 2 p + g 1 u f ; x(0) = x 0 dp dt = a 3 x − a 4 p + g 2 u p ; p(0) = p 0 . h(t), the hormone present at the same time t; p(t), the rate of increase of glucose in the blood; u(t), the rate of increase of insulin in the blood.
System (2.1) above exhibits two mechanisms for the control of uric acid namely diet which changes the value of g 1 and medication (drug) which changes the value of g 2 .
Notice that we have made use of the following facts in determining the signs of a 1 , a 2 , a 3 , a 4 :
(i) When serum uric acid begins to crystallize into urate crystals which are deposited in joints and tissues, the concentration of serum uric acid decreases accordingly, hence a 1 > 0.
(ii) Uricase causes a decrease in the concentration of serum uric acid, hence a 2 > 0.
(iii) When uric acid level rises, more uricase will be injected into the blood, to increase the rate of chemical reaction, hence a 3 < 0.
(iv) When the enzyme/catalyst uricase increases the rate at which serum urate molecules binds with plasma protein to form serum soluble metabolites which can be promptly excreted, the concentration of uricase in the blood remains constant hence a 4 > 0.
Model Solution
We shall first establish the existence of bounded solutions of our system of equations by the following theorem.
Theorem 3.1 There exists bounded solutions for the system of Equation (2.1), for
Proof. From the first equation in system (2.1) above, we have
The substitution of the value of p from Equation (3.1) into the second equation in system (2.1) yields
Let t 1 > 0 be the time when the exogeneous supply of serum uric acid reduces to zero. In which case u f = u p = 0. Then Equation (3.2) becomes
The auxiliary equation for Equation (3.3) is
For (a 1 + a 4 ) 2 < 4 (a 4 a 1 + a 3 a 2 ), the solution of Equation (3.3) is given by 
Some Controllability and Stabilizability Results
In considering the controllability and stabilizability problem of a particle whose trajectory is determined by the system
we shall adopt the following conditions:
(a) At time t < t 0 , (where t 0 is the time when drug is first applied), we have x < 7 which implies that no drug is applied when serum uric acid level is less than 7mg/dl.
(c) At final time t 1 , we have x(t 1 ) = 0 which means that drugs reduce excess serum uric acid level to zero at time t 1 implying that the patient is cured at time t 1 .
We shall identify the following classes of patients: (i) Class of patients on improper diet but with no kidney malfunction (asymptomatic stage).
(ii) Class of patients on improper diet but with kidney malfunction (critical stage).
(iii) Class of patients on proper diet and with no kidney malfunction (rest period).
(iv) Class of patients on proper diet and with kidney malfunction (hazard stage).
Definition of terms
(a) By a proper diet, we mean a combination of purine free food and drugs.
(b) By an improper diet, we mean a combination of purine rich food and drugs.
(c) By kidney malfunction, we mean the inability of the kidney to promptly excrete uric acid.
Assumptions
A 1 : Hyperuricemia is more a result of underexcretion of uric acid, than that of oversecretion of uric acid.
A 2 : All forms of underexcretion of uric acid is due to kidney malfunction. 
H 3 : Patient has no kidney malfunction ⇒ u p = 0.
Analysis
Under assumption A 1 , we shall consider the following cases:
Case 1 (Class of Patients on Improper Diet and with Kidney Malfunction)
In this case, u f 0, u p 0 and our system of equations are
If u is the optimal combination of food and drug that can bring about a cure without fear of malnutrition or www.ccsenet.org/jmr Vol. 4, No. 4; 2012 overdose, then we can write system (4.2) in matrix form as follows:
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If the rate of supply g 1 of dietary purine and the rate of supply g 2 of puricase are equal to g say, then our system of equations can be written as:
Case 2 (Class of Patients on Proper Diet but with no Kidney Malfunction)
In this case, u f = 0 and u p = 0, and our system of equations become Proof. For the system above,
On expansion, we obtain the quadratic equation
Hence,
Consequently, the zero solution of the linearized system is a stable node if (a 1 a 4 ) 2 ≥ 4a 2 a 3 and a stable focus if (a 1 a 4 ) 2 < 4a 2 a 3 .
Case 3 (Class of Patients on Proper Diet but with Kidney Malfunction)
In this case, u f = 0, u p 0, and the only source of uric acid will be considered to stem from slight disorders in the metabolic pathway of endogeneous purine.
Our system of equations then become:
where ε represents some disorder (perturbation) in purine metabolic pathways triggered off by the use of drugs like diuretics which prevents urine retention in kidney malfunction patients. Such drugs cause dehydration and a resultant increase in the concentration of serum uric acid. To prevent such increase, more puricase has to be injected into the blood. This will in turn increase a 2 . To effect a cure, ε must be minimized, while a 2 must be increased by a steady increase in u p . This may produce two effects:
(i) a blow-up (instability) of the term a 2 ε with time (at infinity); (ii) an overdose of the drug puricase. Vol. 4, No. 4; 2012 Proof. We rewrite system (4.4) in matrix form as
This implies that
The controllability matrix for system (4.5) is given by
The matrix C has two linearly independent rows (that is C is of rank 2), and A has order 2. Therefore we arrive at the following conclusions:
(i) That system (4.5) is completely controllable implying that complications such as chronic topheceous gouty arthritis which may lead to stiffness, crippling and deformity can be prevented and hence cure may be effected in finite time through drug action, for a patient on proper diet.
(ii) Subsequent attacks following an initial episode can be arrested in finite time. From the equation
we have ε dx dt + −a 1 εx = −a 2 p which implies that
thus, safe levels of uric acid may be attained by using large doses of drugs, but this may induce dangerous sideeffects. Moreover, such drugs may be rather too expensive.
To balance up the two effects, Hocking (1991) employed the following cost functional
where t 1 is the equilibrium time during which u is reduced to zero, g is the amount of glucose, u is the amount of insulin and k 2 is the weighting factor between the two cost components. Employing Equation (4.6) above, and modeling after Hocking (1991), we shall define our cost function as
where u f and u p are defined as in section 2 and a 1 represents the rate at which serum uric acid crystallizes into urate.
Exponential decay stems from the fact that the concentration of serum uric acid decreases in a simple exponential way, as uric acid crystallizes into urate salt, which settles in the joints and tissues with k as the relative importance of malnutrition and overdose. In the fixed endpoint problem, terminal conditions are required. Hence we shall introduce the adjoint (co-state) variables p 1 and p 2 and state our terminal conditions as follows p 1 (t 1 ) = p 2 (t 2 ) = 0.
Our next task is to minimize the cost function. This is achieved by first obtaining the optimal control function and using same to replace all the control variables in the subsequent equations.
It is worthy of note that the carrier of the optimal control function in question is the Hamiltonian which in the study by O'malley and Kung (1975) is represented by the equation
where the angled brackets ·, · represent a scalar product. In the context under consideration, the Hamiltonian takes the form
Along the optimal trajectory, the derivative of the Hamiltonian with respect to the control variable u p must be equals to zero, that is, ∂H ∂u p = 0, (4.8) a condition typified by PONTRYAGIN'S MAXIMUM PRINCIPLE. By virtue of this principle, Equation (4.8) is quickly reduced to the form 2e
then our u p will minimize J. Therefore u p is an OPTIMAL CONTROL, since it minimizes J over all admissible inputs (controls).
Case 4 (The Critical Case)
In this case, two conditions abound:
(a) the rate a 1 at which serum uric acid crystallizes into urate crystals is so high that a 1 ε does not tend to zero as ε → 0.
(b) the corresponding rate a 3 at which the concentration of the drug puricase is increasing is so high that a 3 ε does not tend to zero as ε → 0.
We shall let a 1 ε = α and a 3 ε = β so that system (4.4) now becomes
www.ccsenet.org/jmr Vol. 4, No. 4; 2012 and Equations (4.7) and (4.8) can be written as ⎧ ⎪ ⎪ ⎨ ⎪ ⎪ ⎩ ε dp 1 dt = αp 1 − βp 2 dp 2 dt = a 2 p 1 + a 4 p 2 .
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(4.10)
Substituting u p = − 1 2 e −a 1 t g 2 p 2 into system (4.9), we obtain the following system of equations
In matrix form we have
In the limit as ε → 0, we have the reduced system of the reduced problem can be written in matrix form as
The coefficient matrices in (4.15) are nonsingular in the sense that the following conditions are satisfied:
Therefore the reduced system has a unique solution.
Case 5 (Puricase is Perturbed by the Action of Certain Inhibiting Enzymes)
In this case, our system of equations become
From the first equation in system (4.17), we have
www.ccsenet.org/jmr Vol. 4, No. 4; 2012 From Equation (4.18), we shall conclude that at the point when all inhibiting factors have been eliminated (ε = 0), continuous application of puricase (in which case a 4 = 0), will progressively (in the limit as t → ∞) eliminate stores of serum uric acid.
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Case 6 (The Hazardous Case)
This case may stem from genetic or hereditary factors or from other disease conditions. In this case serum uric acid level becomes very high, and we may adopt a cost functional that is linear in u p , and quadratic in x. We shall define our cost functional as
and our optimal control problem shall be defined as:
subject to system (4.4), where k 1 is the cost of prevention and k 2 is the cost of treatment.
Since the cost k 2 of treatment is directly proportional to the rate g 2 of supply of the drug puricase, we shall let k 2 = αg 2 , where α is an arbitrary constant. Moreover, the aim of treatment is to prevent an attack of gout and the cost k 1 of prevention is directly proportional to the cost k 2 of treatment. That is, k 1 = βαg 2 .
Theorem 4.3 The optimal amount of serum uric acid resulting from proper diet and optimal dosage of puricase depends on the rate a 1 at which serum uric acid crystallizes into urate.
Proof. Employing the facts above, we can rewrite our cost functional as
Corresponding to system (4.4), the Hamiltonian function to be minimized is given by:
Differentiating the first equation in system (4.4) once with respect to t yields:
Substituting the value of dp dt from the second equation of system (4.4) into Equation (4.19) yields: (4.20) Substituting the value of u p dt derived from Equation (4.20) into our cost functional, we obtain the line integral
Journal of Mathematics Research Vol. 4, No. 4; 2012 along any curve C in the (x, t) space. We shall apply the Green's theorem to our line integral over an area R bounded by C to obtain:
where ε 1 = a 1 ε.
As it stands, ε → 0 faster than ε 1 . Hence in the limit as ε → 0, Equation (4.21) becomes
To specify our optimal control, we need to partition the (t, x 1 ) space into regions where the integrand in Equation (4.22) above takes positive and negative values. Equating the integrand in Equation (4.22) to zero, we have:
Application of Boundary Layer Analysis to a Singularly Perturbed Model of the Gout Disease
Gout is a metabolic disorder in which excess uric acid is produced and deposited mostly in the joints. Note that a joint depicts the junction or boundary between two bones.
In this section we shall carry out some boundary layer analysis on our singularly perturbed model of the gout disease. Generally substrate (urate) velocity increases across the boundary layer (the joint), causing a corresponding increase in temperature around the affected joint, which in turn may lead to an attack. This increase in temperature in turn increases the particle deposition rate (Joshua, 2008) .
Fluid velocity increases across the boundary layer, reaching its peak value and then decreasing to the free stream velocity value. Possible heat generation effects may alter the temperature distribution and the particle deposition rate.
Boundary layer analysis involves the matching of the inner (fast transient) solution x i (τ, ε), y i (τ, ε) (also called the boundary layer correction), which approaches zero and the outer (slow decay) solution x 0 (t, ε), y 0 (t, ε). The matching is done through a stretching (straining) transformation τ = t ε . Since they just represent two pieces of the same trajectory, the inner and outer solutions have to match up in an intermediate time range, through the stretching (straining) transformation. In composite form whose terms all decay to zero as the stretched variable τ = t ε tends to ∞. Then the asymptotic solution for each fixed t > 0 will be given to all orders by the outer solution. The outer solution is supposed to be valid when is not too small while the inner solution is valid when τ is not too large (Roussel, 2005) .
In our analysis, the function x i t ε , ε , y i t ε , ε will be called the boundary layer solution (or correction term). Our controllable process shall be partitioned into 2 phases namely: The build up of high serum urate levels (triggers), and the onset of gouty arthritis (1 st attack). Whereas the build up is slow, the onset of attack is fast and can only be described in a continuous time model. We shall therefore identify two adjoining regions (subdomains) and two time variables namely: a slow time variable (t) and a fast time variable (τ).We shall consider two adjoining domains: an inner (boundary layer, 0 < t < t 0 ) domain representing the ligament and an outer (t 0 < t < t 1 ) domain representing the tendon. 
